Stock Markets January 22, 2026

Inspire Medical Faces Stock Pressure After CMS Withdraws Sleep Apnea Coverage

Regulatory change prompts analyst downgrades amid reimbursement concerns

By Ajmal Hussain INSP
Inspire Medical Faces Stock Pressure After CMS Withdraws Sleep Apnea Coverage
INSP

Shares of Inspire Medical Systems declined sharply following the Centers for Medicare & Medicaid Services' decision to exclude obstructive sleep apnea (OSA) as a covered condition under CPT code 64568. The revision requires Medicare Administrative Contractors to individually assess claims, leading to lowered analyst expectations and adjustments in price targets.

Key Points

  • CMS removed obstructive sleep apnea as a covered diagnosis for CPT code 64568 under NCD 160.18, shifting coverage decisions to individual Medicare Administrative Contractors.
  • Following the CMS update, Inspire Medical's stock price dropped sharply due to concerns over reimbursement and prospects.
  • Financial analysts revised ratings and price targets: Oppenheimer and Truist Securities downgraded Inspire Medical, while Evercore ISI kept an Outperform rating anticipating stable guidance.

Inspire Medical Systems (NYSE:INSP) experienced a significant drop in its stock price, falling 12.6% on Thursday due to a notable change by the Centers for Medicare & Medicaid Services (CMS). The regulatory body updated its policy to exclude obstructive sleep apnea (OSA) from the list of covered diagnoses for the CPT code 64568 under National Coverage Determination (NCD) 160.18.

The CMS clarification revealed that the ICD-10 diagnosis code for OSA (G47.33) had been mistakenly included as an approved indication for coverage and was subsequently removed. Consequently, coverage determinations for this condition are now delegated to individual Medicare Administrative Contractors (MACs), which will adjust claims affected by this modification accordingly.

This regulatory shift prompted multiple financial institutions to reassess their evaluations of Inspire Medical's prospects. Oppenheimer downgraded its rating on Inspire Medical from Outperform to Perform citing apprehensions related to reimbursement challenges. Similarly, Truist Securities revised their stance from Buy to Hold and decreased the price target from $120.00 to $96.00.

Truist analyst Richard Newitter explained that the downgrade stemmed from a "diminished confidence in estimated upside prospects without any pricing tailwinds now that INSP can no longer officially use the 64568 code." He also noted that the firm had previously upgraded Inspire Medical in late November based on anticipated price increases that are now considered unlikely.

In contrast, Evercore ISI maintained an Outperform rating with a price target of $125.00, arguing that the company's fiscal year 2026 guidance remains valid as "no significant reimbursement uplift was assumed." Evercore expects Inspire Medical’s reimbursement rates to effectively revert to those of 2025.

The CMS decision effectively reverses a prior adjustment made in November 2025 when CPT code 64568 had been reassigned to APC 1580, a move that would have raised reimbursements by approximately 50% in hospital and ambulatory surgical center settings.

Risks

  • Potential reduction in reimbursement levels for Inspire Medical due to CMS policy changes affecting sleep apnea coverage, impacting revenue prospects.
  • Uncertainty surrounding Medicare Administrative Contractors' decisions could lead to inconsistent claim approvals and financial unpredictability.
  • Loss of expected pricing tailwinds linked to CPT code 64568 removal introduces downside risk to Inspire Medical's growth estimates.

More from Stock Markets

Draganfly Shares Jump After Win to Supply Flex FPV Drones and Training to Air Force Special Ops Feb 2, 2026 Peakstone Realty Trust to Be Taken Private by Brookfield; Shares Jump 33% Feb 2, 2026 Beyond Inc. Moves to Build Unified Investment and Personal Finance Platform with Tokens.com Deal Feb 2, 2026 Eton Pharmaceuticals Gains After Securing U.S. Rights to Ultra-Rare Disease Candidate Feb 2, 2026 Morgan Stanley Survey: Broader Consumer Sentiment Improves While Electronics Spending Intentions Slip Feb 2, 2026